More than 100,000 patients have been treated with ustekinumab and aggregated safety data from more than 20,000 patients have demonstrated an impressive safety profile, with sepsis rates consistently lower than anti-tumor necrosis factor (TNF) inhibitors, better preservation of vaccine responses22–26 and no increased cancer risk compared with anti-TNF inhibitors27. The gene discussed is TNF; the disease is Sepsis.